FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224860695> ?p ?o ?g. }

• W4224860695 endingPage "1519" @default.
• W4224860695 startingPage "1510" @default.
• W4224860695 abstract "Invasive pneumococcal disease (IPD) and a variety of clinical syndromes caused by pneumococci, such as acute otitis media (AOM), acute sinusitis (AS), and community-acquired pneumonia (CAP), cause a substantial burden on healthcare systems. Few studies have explored the short-term financial burden of pneumococcal disease after the 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the infant immunization programs. This population-based study evaluated changes in costs associated with healthcare utilization for pneumococcal disease after the PCV13 introduction in the infant immunization program in British Columbia, Canada.Individuals with pneumococcal disease were identified using provincial administrative data for the 2000 to 2018 period. Total direct healthcare costs were determined using case-mix methodology for hospitalization and fee-for-service codes for outpatient visits and medications dispensed. Costs were adjusted to 2018 Canadian dollars. Changes in the annual healthcare costs were evaluated across vaccine eras (pre-PCV13, 2000-2010; PCV13, 2011-2018) using generalized linear models, adjusting for the 7-valent pneumococcal conjugate vaccine program (2004-2010).During the 19-year study period, pneumococcal disease resulted in 6.3 million cases among 85 million total patient-years, resulting in total healthcare costs of $7.9 billion. More than 6.2 million cases were treated in outpatient setting, costing $0.65 billion (8% of total costs associated with pneumococcal disease treatment), whereas 370 000 hospitalized cases were 3% of all cases, which accrued $7.25 billion (92% of total costs) in costs. Healthcare costs for all studied infections nearly doubled over the study period from $248 million in 2000 to $476 million in 2018 (P = .003). In contrast, there were large declines in total annual costs in the PCV13 era for IPD (adjusted relative rate (aRR) 0.73; 95% confidence interval [CI] 0.56-0.95; P = .032), AOM (aRR 0.70; 95% CI 0.59-0.83; P = .001), and AS (aRR 0.68; 95% CI 0.54-0.85; P = .004) compared with the pre-PCV13 era. Total costs increased marginally in the PCV13 era for all-cause CAP (aRR 1.04; 95% CI 0.94-1.15; P = .484).This study confirms a temporal association in declining economic burden for IPD, AOM, and AS after the PCV13 introduction. Nevertheless, the total economic burden continues to be high in the PCV13 era, mainly driven by increasing CAP costs." @default.
• W4224860695 created "2022-04-27" @default.
• W4224860695 creator A5009737392 @default.
• W4224860695 creator A5017594981 @default.
• W4224860695 creator A5020898730 @default.
• W4224860695 creator A5054105827 @default.
• W4224860695 creator A5062661267 @default.
• W4224860695 creator A5066501041 @default.
• W4224860695 date "2022-09-01" @default.
• W4224860695 modified "2023-09-23" @default.
• W4224860695 title "Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study" @default.
• W4224860695 cites W1738852887 @default.
• W4224860695 cites W1981615629 @default.
• W4224860695 cites W1993861490 @default.
• W4224860695 cites W2000714505 @default.
• W4224860695 cites W2023748147 @default.
• W4224860695 cites W2038507666 @default.
• W4224860695 cites W2039768024 @default.
• W4224860695 cites W2041616439 @default.
• W4224860695 cites W2047469931 @default.
• W4224860695 cites W2067272655 @default.
• W4224860695 cites W2075695356 @default.
• W4224860695 cites W2147712236 @default.
• W4224860695 cites W2223743203 @default.
• W4224860695 cites W2277520534 @default.
• W4224860695 cites W2305875831 @default.
• W4224860695 cites W2322064713 @default.
• W4224860695 cites W2376628495 @default.
• W4224860695 cites W2559766601 @default.
• W4224860695 cites W2759491490 @default.
• W4224860695 cites W2805807825 @default.
• W4224860695 cites W2808117202 @default.
• W4224860695 cites W2891849294 @default.
• W4224860695 cites W2892082049 @default.
• W4224860695 cites W2962868134 @default.
• W4224860695 cites W2972988014 @default.
• W4224860695 cites W2995115404 @default.
• W4224860695 cites W3011259367 @default.
• W4224860695 cites W3015254618 @default.
• W4224860695 cites W3090822763 @default.
• W4224860695 cites W3133465291 @default.
• W4224860695 cites W3162003009 @default.
• W4224860695 cites W3199556634 @default.
• W4224860695 cites W3209064482 @default.
• W4224860695 cites W4206578657 @default.
• W4224860695 cites W4239909494 @default.
• W4224860695 cites W48044459 @default.
• W4224860695 doi "https://doi.org/10.1016/j.jval.2022.03.017" @default.
• W4224860695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35466049" @default.
• W4224860695 hasPublicationYear "2022" @default.
• W4224860695 type Work @default.
• W4224860695 citedByCount "0" @default.
• W4224860695 crossrefType "journal-article" @default.
• W4224860695 hasAuthorship W4224860695A5009737392 @default.
• W4224860695 hasAuthorship W4224860695A5017594981 @default.
• W4224860695 hasAuthorship W4224860695A5020898730 @default.
• W4224860695 hasAuthorship W4224860695A5054105827 @default.
• W4224860695 hasAuthorship W4224860695A5062661267 @default.
• W4224860695 hasAuthorship W4224860695A5066501041 @default.
• W4224860695 hasBestOaLocation W42248606951 @default.
• W4224860695 hasConcept C126322002 @default.
• W4224860695 hasConcept C147483822 @default.
• W4224860695 hasConcept C160735492 @default.
• W4224860695 hasConcept C162324750 @default.
• W4224860695 hasConcept C187212893 @default.
• W4224860695 hasConcept C203014093 @default.
• W4224860695 hasConcept C2776152631 @default.
• W4224860695 hasConcept C2777914695 @default.
• W4224860695 hasConcept C2778866548 @default.
• W4224860695 hasConcept C2780801004 @default.
• W4224860695 hasConcept C2781253189 @default.
• W4224860695 hasConcept C2908647359 @default.
• W4224860695 hasConcept C501593827 @default.
• W4224860695 hasConcept C50522688 @default.
• W4224860695 hasConcept C71924100 @default.
• W4224860695 hasConcept C86803240 @default.
• W4224860695 hasConcept C89423630 @default.
• W4224860695 hasConcept C99454951 @default.
• W4224860695 hasConceptScore W4224860695C126322002 @default.
• W4224860695 hasConceptScore W4224860695C147483822 @default.
• W4224860695 hasConceptScore W4224860695C160735492 @default.
• W4224860695 hasConceptScore W4224860695C162324750 @default.
• W4224860695 hasConceptScore W4224860695C187212893 @default.
• W4224860695 hasConceptScore W4224860695C203014093 @default.
• W4224860695 hasConceptScore W4224860695C2776152631 @default.
• W4224860695 hasConceptScore W4224860695C2777914695 @default.
• W4224860695 hasConceptScore W4224860695C2778866548 @default.
• W4224860695 hasConceptScore W4224860695C2780801004 @default.
• W4224860695 hasConceptScore W4224860695C2781253189 @default.
• W4224860695 hasConceptScore W4224860695C2908647359 @default.
• W4224860695 hasConceptScore W4224860695C501593827 @default.
• W4224860695 hasConceptScore W4224860695C50522688 @default.
• W4224860695 hasConceptScore W4224860695C71924100 @default.
• W4224860695 hasConceptScore W4224860695C86803240 @default.
• W4224860695 hasConceptScore W4224860695C89423630 @default.
• W4224860695 hasConceptScore W4224860695C99454951 @default.
• W4224860695 hasFunder F4320307765 @default.
• W4224860695 hasIssue "9" @default.

• next